Insulin aspart, recombinant Subcutaneous and Omadacycline Intravenous
Determining the interaction of Insulin aspart, recombinant Subcutaneous and Omadacycline Intravenous and the possibility of their joint administration.
No interaction was detected between the selected drugs or effects of joint drug administration are currently understudied, and it takes time and accumulated statistics to determine their interaction. A doctor should be consulted to address the issue of joint drug administration.
Generic Name: insulin aspart
Brand name: Fiasp, NovoLog, NovoLog FlexPen, NovoLog PenFill, NovoLOG FlexTouch, Fiasp PenFill, Fiasp FlexTouch
Synonyms: Insulin aspart, Insulin Aspart
Generic Name: omadacycline
Brand name: Nuzyra
Synonyms: Omadacycline (oral/injection), Omadacycline
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Insulin aspart, recombinant Subcutaneous-Omadacycline oral/injection
- Insulin aspart, recombinant Subcutaneous-Omadacycline Tablets
- Insulin aspart, recombinant Subcutaneous-Omadacycline Tosylate
- Insulin aspart, recombinant Subcutaneous-Omalizumab
- Insulin aspart, recombinant Subcutaneous-Omalizumab Subcutaneous
- Insulin aspart, recombinant Subcutaneous-Ombitasvir, Paritaprevir, and Ritonavir
- Omadacycline Intravenous-Insulin degludec
- Omadacycline Intravenous-Insulin Degludec (U-100) Prefilled Pens
- Omadacycline Intravenous-Insulin Degludec (U-100) Vials
- Omadacycline Intravenous-Insulin Degludec (U-200) Prefilled Pens
- Omadacycline Intravenous-Insulin degludec and liraglutide
- Omadacycline Intravenous-Insulin degludec and liraglutide Subcutaneous